{"id":391119,"date":"2016-06-14T00:00:00","date_gmt":"2016-06-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latrim0028-2016-biopharma-psoriasis-emerging-therapies-cosentyx-secukinumab-us-wave-3-2016\/"},"modified":"2026-04-17T11:41:59","modified_gmt":"2026-04-17T11:41:59","slug":"latrim0028-2016-biopharma-psoriasis-emerging-therapies-cosentyx-secukinumab-us-wave-3-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latrim0028-2016-biopharma-psoriasis-emerging-therapies-cosentyx-secukinumab-us-wave-3-2016\/","title":{"rendered":"Psoriasis | Emerging Therapies | Cosentyx (secukinumab) | US | Wave 3 | 2016"},"content":{"rendered":"<p><em>Cosentyx (US)\u00a0<\/em>is a three-wave syndicated report series that specifically tracks the introduction of Novartis\u2019s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor approved for the treatment of psoriasis (PsO). This report series is based on primary research data collected at one month, six months, and one year post-commercial availability of Cosentyx. Along with awareness and sources of familiarity, the reports assess U.S. dermatologists\u2019 trial, adoption, and use of Cosentyx, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Novartis\u2019s promotional efforts, and benchmarking against other previously launched immune agents.<\/p>\n","protected":false},"template":"","class_list":["post-391119","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-product-emerging-therapies","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391119\/revisions"}],"predecessor-version":[{"id":394242,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391119\/revisions\/394242"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}